Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Su Y, et al. Among authors: behrens cr. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6. JCI Insight. 2018. PMID: 30185663 Free PMC article.
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Sherbenou DW, et al. Among authors: behrens cr. Clin Cancer Res. 2020 Nov 15;26(22):6028-6038. doi: 10.1158/1078-0432.CCR-20-0400. Epub 2020 Sep 11. Clin Cancer Res. 2020. PMID: 32917735 Free PMC article.
The development of potential antibody-based therapies for myeloma.
Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. Sherbenou DW, et al. Among authors: behrens cr. Blood Rev. 2015 Mar;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub 2014 Sep 28. Blood Rev. 2015. PMID: 25294123 Free PMC article. Review.
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Sherbenou DW, et al. Among authors: behrens cr. J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14. J Clin Invest. 2016. PMID: 27841764 Free PMC article.
Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY. Behrens CR, et al. Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2. Mol Pharm. 2015. PMID: 26393951 Free PMC article.
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
Fairman J, Agarwal P, Barbanel S, Behrens C, Berges A, Burky J, Davey P, Fernsten P, Grainger C, Guo S, Iki S, Iverson M, Kane M, Kapoor N, Marcq O, Migone TS, Sauer P, Wassil J. Fairman J, et al. Vaccine. 2021 May 27;39(23):3197-3206. doi: 10.1016/j.vaccine.2021.03.070. Epub 2021 May 6. Vaccine. 2021. PMID: 33965258 Free article.
13 results